A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs ACH 4471 (Primary)
- Indications Membranoproliferative glomerulonephritis
- Focus Therapeutic Use
- Sponsors Achillion Pharmaceuticals
- 11 Sep 2017 According to an Achillion Pharmaceuticals media release, initiation of dosing is expected in the second half of 2017.
- 11 Jul 2017 Status changed from not yet recruiting to recruiting.
- 28 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Jul 2017.